Pfizer Canada (PFE) and BioNTech (BNTX) announced that Health Canada has authorized the companies’ Omicron XBB.1.5-adapted monovalent COVID-19 vaccine for ages six months and older. The updated vaccine will be available in Canada as a single dose for individuals five years of age and older, regardless of prior COVID-19 vaccination history.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PFE:
- Unusually active option classes on open September 29th
- Ginkgo Bioworks announces multi-target RNA discovery collaboration with Pfizer
- Biotech Alert: Searches spiking for these stocks today
- Pfizer says CDC’s ACIP issued ‘favorable vote’ for Abrysvo for RSV
- CDC panel votes to back Pfizer maternal RSV vaccine, Bloomberg reports
